Wells Fargo’s Akari Therapeutics AKTX Stock Holding History

Wells Fargo’s Portfolio AKTX Stock Details AKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1	Closed	-$7K	–	6195
2017 Q1	$7K	Buy	+1	New	+$5.6K	﹤0.01%	5957
2015 Q2	–	Hold	0	–	-$1K	–	6318
2015 Q1	–	Hold	0	–	–	–	6031

Other funds holding AKTX

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Wells Fargo's AKTX Position: Q2 2017 in Review

Wells Fargo sold out of Akari Therapeutics (AKTX) in Q2 2017, closing a stake of 1 share — an estimated $7K sold.

Wells Fargo first reported a position in AKTX in Q1 2017 and held it in 1 quarter. The position peaked at $7K in Q1 2017. 14 funds tracked by Wall St. Rank hold AKTX as of Q2 2017.

Wells Fargo reported no remaining Akari Therapeutics position as of Q2 2017 after selling out during the quarter.
Wells Fargo sold 1 Akari Therapeutics share in Q2 2017, an estimated $7K.
Wells Fargo first reported a position in Akari Therapeutics in Q1 2017 and held it in 1 quarter.
Wells Fargo's Akari Therapeutics position peaked at $7K in Q1 2017.
14 funds tracked by Wall St. Rank held Akari Therapeutics as of Q2 2017.

Based on Wells Fargo's 13F filing for Q2 2017, filed 10 Aug 2017.